Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS

NCT01583374 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01583374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01583374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
May 2, 2012
Completion date
October 25, 2018
Enrollment
490 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondyloarthritis